ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Highly-sensitized"

  • 2018 American Transplant Congress

    Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)

    S. Patel, S. Mohan, H. Fernandez, I. Batal, L. Ratner, J. Crew.

    Columbia University, New York.

    INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…
  • 2018 American Transplant Congress

    Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)

    J. Choi,1 O. Aubert,2 S. Louie,1 N. Ammerman,1 A. Vo,1 A. Peng,1 E. Huang,1 R. Najjar,1 D. Puliyanda,1 S. Sethi,1 M. Haas,1 K. Lim,1 A. Loupy,2 S. Jordan.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Paris Translational Center for Organ Transplantation, Paris, France.

    Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…
  • 2018 American Transplant Congress

    A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

    R. Najjar, E. Huang, A. Vo, J. Choi, K. Lim, S. Louie, A. Peng, S. Sethi, M. Toyoda, X. Zhang, S. Jordan.

    Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.

    Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…
  • 2018 American Transplant Congress

    Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation

    A. Vo, E. Huang, N. Ammerman, S. Williamson, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.

    Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…
  • 2018 American Transplant Congress

    Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation

    S. Jordan,1 J. Choi,1 E. Huang,1 R. Najjar,1 A. Peng,1 X. Zhang,1 S. Louie,1 M. Haas,2 S. Sethi,1 I. Kim,1 A. Vo.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…
  • 2018 American Transplant Congress

    Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation

    A. Jackson,1 B. Iglehart,1 S. Bagnasco,3 N. Desai.2

    1Medicine, Johns Hopkins University, Baltimore, MD; 2Surgery, Johns Hopkins University, Baltimore, MD; 3Pathology, Johns Hopkins University, Baltimore, MD.

    Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
  • 2017 American Transplant Congress

    Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.

    A. Vo, J. Choi, A. Peng, K. Lim, L. Varanasi, R. Najjar, E. Huang, D. Puliyanda, S. Jordan.

    Kidney Transplant, Cedars-Sinai Medical Center, LA, CA

    INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…
  • 2017 American Transplant Congress

    Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.

    A. Vo,1 S. Williamson,1 K. Myers,1 E. Huang,1 J. Choi,1 X. Zhang,2 A. Peng,1 R. Najjar,1 S. Jordan.1

    1Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; 2HLA Laboratory, Cedars-Sinai Medical Center, LA, CA

    Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…
  • 2017 American Transplant Congress

    Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.

    S. Patel,1 J. Benken,1 S. Akkina,3 P. West-Thielke,2 J. Thielke,1 M. Campara,1 J. Oberholzer,2 E. Benedetti.2

    1Pharmacy, University of Illinois Hospital & Health Sciences System, Chicago; 2Surgery, University of Illinois Hospital & Health Sciences System, Chicago; 3Medicine, Loyola University Health System, Maywood

    Purpose: To determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to a negative flow cytometry crossmatch (FCXM) despite desensitization. Methods:…
  • 2017 American Transplant Congress

    Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.

    S. Sethi, A. Vo, E. Huang, L. Varanasi, J. Choi, A. Peng, R. Najjar, S. Jordan.

    Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

    IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences